Header Logo

Connection

NICOLA HANANIA to Omalizumab

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Omalizumab.
NICOLA HANANIA
Connection Strength
3.288
Omalizumab
  1. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
    View in: PubMed
    Score: 0.647
  2. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.634
  3. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.582
  4. Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
    View in: PubMed
    Score: 0.224
  5. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
    View in: PubMed
    Score: 0.191
  6. Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 06; 8(6):2068-2070.
    View in: PubMed
    Score: 0.171
  7. Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. J Allergy Clin Immunol Pract. 2020 02; 8(2):507-515.e10.
    View in: PubMed
    Score: 0.165
  8. IgE-mediated asthma: New revelations and future insights. Respir Med. 2016 Mar; 112:128-9.
    View in: PubMed
    Score: 0.128
  9. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.107
  10. Targeting IgE in asthma. Curr Opin Pulm Med. 2012 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.098
  11. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.093
  12. Targeting airway inflammation in asthma: current and future therapies. Chest. 2008 Apr; 133(4):989-98.
    View in: PubMed
    Score: 0.075
  13. Effectiveness of omalizumab across different dosing regimens in patients with moderate-to-severe allergic asthma. Respir Med. 2024 03; 223:107537.
    View in: PubMed
    Score: 0.056
  14. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1043-1057.
    View in: PubMed
    Score: 0.044
  15. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
    View in: PubMed
    Score: 0.043
  16. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014 Sep-Oct; 2(5):525-36.e1.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.